In summary, our study suggests that elevated NT-proBNP levels are very common and not predictive of CVAE whereas low levels of hsTropI demonstrated a negative predictive value for the occurrence of CVAE in high-risk newly diagnosed MM patients in the CONCEPT trial undergoing carfilzomib-based Isa-KRd treatment. The gene discussed is NPPB; the disease is Miyoshi myopathy.